Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O00571
UPID:
DDX3X_HUMAN
Alternative names:
CAP-Rf; DEAD box protein 3, X-chromosomal; DEAD box, X isoform; Helicase-like protein 2
Alternative UPACC:
O00571; A8K538; B4E3E8; O15536
Background:
ATP-dependent RNA helicase DDX3X, known by alternative names such as CAP-Rf and DEAD box protein 3, X-chromosomal, plays a pivotal role in cellular processes including transcription regulation, mRNA transport, and translation initiation. Its ability to unwind partially double-stranded DNA and bind RNA G-quadruplex structures underlines its multifaceted functionality in RNA metabolism.
Therapeutic significance:
DDX3X's involvement in Intellectual developmental disorder, X-linked, syndromic, Snijders Blok type, characterized by intellectual disability and epilepsy, highlights its potential as a therapeutic target. Understanding the role of ATP-dependent RNA helicase DDX3X could open doors to potential therapeutic strategies.